Scientific Advisory Board

 Allen Ebens, B.Sc., Ph.D.

Allen Ebens, B.Sc., M.D., Ph.D.

Dr. Allen Ebens completed a PhD at UCLA and Post-doctoral training at UCSF before joining Exelixis as a scientist in the Discovery Biology group. After 6 years with Exelixis Dr. Ebens moved to Genentech where he worked in Research Oncology for 11 years developing therapeutics from concept to clinic across multiple therapeutic platforms including antibodies, small molecule drugs, and antibody-drug conjugates. Dr. Ebens was recruited from Genentech to establish Research Oncology at Juno Therapeutics, and has served more recently as Senior Director of Immune Oncology at NGM Biopharmaceuticals.  Dr. Ebens is currently Chief Scientific Officer of Trucode Gene Repair.  Over a twenty year career Dr. Ebens’ contributions include significant contributions to the scientific literature as well as advancement of five discovery projects to clinical development.


 Peter Ordentlich, B.Sc., Ph.D.

Dr-Peter-OrdentlichDr Peter Ordentlich completed a PhD in Immunology at the University of Pennsylvania and a Post-Doc at the Salk Institute for Biological Studies before joining X-Ceptor Therapeutics, a discovery stage biotechnology company focused on the identification of novel therapeutics for cardiovascular and oncology indications. Dr Ordentlich spent five years as a research scientist leading multiple lead discovery and optimization projects at X-Ceptor Therapeutics, which was acquired by Exelixis in 2004. In 2005 Dr Ordentlich co-founded Syndax Pharmaceuticals, a NASDAQ-listed, clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies with three clinical stage assets, where he is currently the Chief Scientific Officer.